[HTML][HTML] Cisplatin-based chemotherapy of human cancers
Abstract Cisplatin (cis-diammine-dichloro-platinum II) was initially discovered to prevent the
growth of Escherichia coli and was further recognized for its anti-neoplastic and cytotoxic …
growth of Escherichia coli and was further recognized for its anti-neoplastic and cytotoxic …
[HTML][HTML] Best practice in systemic therapy for head and neck squamous cell carcinoma
SF Oosting, RI Haddad - Frontiers in Oncology, 2019 - frontiersin.org
Treating head and neck cancer patients with systemic therapy is challenging because of
tumor related, patient related and treatment related factors. In this review, we aim to …
tumor related, patient related and treatment related factors. In this review, we aim to …
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non …
Background Patients with human papillomavirus (HPV)-positive oropharyngeal squamous
cell carcinoma have high survival when treated with radiotherapy plus cisplatin. Whether …
cell carcinoma have high survival when treated with radiotherapy plus cisplatin. Whether …
Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial
PURPOSE Nivolumab was assessed in patients with virus-associated tumors in the phase
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …
[HTML][HTML] Integrated analysis of lncRNA-miRNA-mRNA ceRNA network in squamous cell carcinoma of tongue
RS Zhou, EX Zhang, QF Sun, ZJ Ye, JW Liu, DH Zhou… - BMC cancer, 2019 - Springer
Background Numerous studies have highlighted that long non-coding RNAs (lncRNAs) can
bind to microRNA (miRNA) sites as competing endogenous RNAs (ceRNAs), thereby …
bind to microRNA (miRNA) sites as competing endogenous RNAs (ceRNAs), thereby …
Management of the neck in squamous cell carcinoma of the oral cavity and oropharynx: ASCO clinical practice guideline
SA Koyfman, N Ismaila, D Crook, A D'Cruz… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE The aim of the current work is to provide evidence-based recommendations to
practicing physicians and others on the management of the neck in patients with squamous …
practicing physicians and others on the management of the neck in patients with squamous …
Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era
Importance Therapy-related myelodysplastic syndrome or acute myeloid leukemia
(tMDS/AML) is a rare, usually fatal complication of chemotherapy, including certain …
(tMDS/AML) is a rare, usually fatal complication of chemotherapy, including certain …
COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and-independent mechanisms
A Lindemann, AA Patel, NL Silver, L Tang, Z Liu… - Clinical Cancer …, 2019 - AACR
Purpose: TP 53 mutations are highly prevalent in head and neck squamous cell carcinoma
(HNSCC) and associated with increased resistance to conventional treatment primarily …
(HNSCC) and associated with increased resistance to conventional treatment primarily …
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck …
Background Because the addition of nimotuzumab to chemoradiation in patients with locally
advanced head and neck cancer improved outcomes in a phase 2 study, the authors …
advanced head and neck cancer improved outcomes in a phase 2 study, the authors …
[HTML][HTML] Low-dose vs. high-dose cisplatin: lessons learned from 59 chemoradiotherapy trials in head and neck cancer
In locally advanced squamous cell carcinomas of the head and neck (LA-SCCHN),
concurrent chemoradiotherapy is an integral part of multimodality management both in the …
concurrent chemoradiotherapy is an integral part of multimodality management both in the …